FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS Share Price

Certificat

DE000MG33GZ2

Real-time Bid/Ask 10:23:47 04/06/2024 BST
12.65 EUR / 13.03 EUR -9.96% Intraday chart for FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS
Current month+2.52%
1 month+43.46%
Date Price Change
03/06/24 14.26 +2.52%
31/05/24 13.91 -11.96%
30/05/24 15.8 -1.68%
29/05/24 16.07 +10.90%
28/05/24 14.49 -1.96%

Delayed Quote Börse Stuttgart

Last update June 03, 2024 at 11:46 am

More quotes

Static data

Product typeExotische Produkte
Buy / SellCALL
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MG33GZ
ISINDE000MG33GZ2
Date issued 26/04/2024
Strike 48.46 $
Maturity Unlimited
Parity 0.72 : 1
Emission price 10
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 16.77
Lowest since issue 8.7
Spread 0.38
Spread %2.95%

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
38.77 USD
Average target price
57.95 USD
Spread / Average Target
+49.47%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW